1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
2.2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Drug, 2023 (US$ Million)
2.3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Amyotrophic Lateral Sclerosis (ALS) Treatment Market Vendors
3.2. Strategies Adopted by Amyotrophic Lateral Sclerosis (ALS) Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Riluzole
5.3.2. Edaravone
5.3.3. Other


6. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
6.3.Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)

7. UK and European Union Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)

8. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)

9. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
9.3.Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)

10. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
10.3.Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2022-2032, USD (Million)

11. Company Profile
11.1. AB Science
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Avicena Group
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Biogen
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. BrainStorm Therapeutics
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Covis Pharmaceutical Inc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Cytokinetics Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Eisai Co. Ltd.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. GlaxoSmithKline plc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Ionis Pharmaceuticals, Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Mitsubishi Tanabe Pharma Corp.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Neuralstem Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Neuraltus Pharmaceuticals Inc.
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Newron Pharmaceuticals S.p.A.
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
11.14. Pharnext SAS
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Portfolio
11.14.4. Strategic Initiatives
11.15. Q-Therapeutics Inc.
11.15.1. Company Overview
11.15.2. Financial Performance
11.15.3. Product Portfolio
11.15.4. Strategic Initiatives